Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-year, Randomized, Double-masked, Multicenter, Two-arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-related Macular Degeneration

NCT02434328 is registered in ClinicalTrials.gov with Alcon Research as lead sponsor.

NCT NCT02434328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02434328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-year, Randomized, Double-masked, Multicenter, Two-arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-related Macular Degeneration
Lead sponsor
Alcon Research
Phase
Phase 3
Overall status
Completed
Start date
July 28, 2015
Completion date
March 8, 2018
Enrollment
1,048 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

choroidal neovascularization, neovascular age-related macular degeneration